Page last updated: 2024-08-21

pyrazines and ixazomib

pyrazines has been researched along with ixazomib in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L1
Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B1
Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B1
Appel, A1
Abe, M; Fujii, S1
Hu, Y; Wu, P; Zhang, J1
Cavallo, F; Genadieva-Stavric, S; Palumbo, A1
Yagi, H1
Mitsiades, CS1

Reviews

3 review(s) available for pyrazines and ixazomib

ArticleYear
Clinical and marketed proteasome inhibitors for cancer treatment.
    Current medicinal chemistry, 2013, Volume: 20, Issue:20

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine

2013
New approaches to management of multiple myeloma.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome

2014
[Proteasome inhibitor].
    Nihon rinsho. Japanese journal of clinical medicine, 2014, Volume: 72, Issue:6

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin

2014

Other Studies

6 other study(ies) available for pyrazines and ixazomib

ArticleYear
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
    Cancer research, 2010, Mar-01, Volume: 70, Issue:5

    Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; Female; Glycine; HCT116 Cells; HT29 Cells; Humans; Lymphoma; Mice; Mice, SCID; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2010
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-15, Volume: 17, Issue:16

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays

2011
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-01, Volume: 17, Issue:23

    Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2011
Drugs: More shots on target.
    Nature, 2011, Dec-14, Volume: 480, Issue:7377

    Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine

2011
[Molecular targeting agents for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide

2012
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-01, Volume: 33, Issue:7

    Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Glycine; Hematologic Neoplasms; Humans; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin

2015